Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer

Abstract

cisplatin 50 mg/m2 on day 1, gemcitabine starting at 1400 mg/m on days 1 and 8 every 21 days. Subsequent levels were increased by 200 mg/m2. Forty-two patients with metastatic NSCLC were enrolled (37 males; median age 61 years; squamous cell carcinoma 19 patients; performance status 2, in 13 patients; 18 patients had significant weight loss). MTD was found to be 2600 mg/m2 because of DLT in three of six patients: two neutropenic fever and one massive bleeding. Overall toxicity was generally mild consisting mainly of neutropenia. Asthenia was the most common non-hematological effect. Overall response rate was 19 out of 41 patients (46.3%) and median survival was 31 weeks. We conclude that the recommended dose for a phase II dose is gemcitabine 2400 mg/m2 days 1 and 8 as a 30-min infusion when given with cisplatin 50 mg/m2.

Old drugs: new complications

“…Gemcitabine and cisplatin are usually administered in combination to treat a variety of malignancies, such as in the treatment of non-small cell lung carcinoma 10 11. This doublet-based combination treatment may induce vascular events.…”

Bilateral Renal Infarction in a Patient with Lung Carcinoma Treated with Cisplatin and Gemcitabine

“…[1] Cisplatin, a platinum-containing agent, and gemcitabine, a pyrimidine nucleoside antimetabolite, are usually administered in combination to treat a variety of malignancies and appear to be most active in the treatment of non-small cell lung cancer. [2,3] Hitherto hepatic, cutaneous, and ocular veno-occlusive diseases, Raynaud's phenomenon, myocardial infarction, cerebral ischemia, thrombotic microangiopathy, hemolytic-uremic syndrome, arterial distal thrombosis, pulmonary embolism, iliac artery embolism, and deep venous thrombosis in upper and lower limbs have been reported with cisplatin and/or gemcitabine therapy. [1,4,5] A case of acute bilateral renal infarction in a patient with non-small cell lung carcinoma during chemotherapy with cisplatin and gemcitabine is reported here.…”

“…Cisplatin and gemcitabine are usually administered in combination to treat a variety of malignancies, such as in the treatment of non-small cell lung carcinoma. [2,3] Cisplatin and gemcitabine treatment may induce vascular events. [1,4,5,11] It was shown that cisplatin increases platelet reactivity.…”